8-K: Cosmos Health Achieves Record Q3 2025 Revenue & Profit

Cosmos Health Inc. reported record third-quarter 2025 financial results, driven by significant revenue and gross profit growth across all core business segments and a strengthened cash position.

Summary

• Record Q3 2025 revenue reached $17.11 million, marking a 38% increase from Q3 2024.
• Record Q3 2025 gross profit was $2.60 million, up 116% compared to Q3 2024.
• Gross margin expanded to a record 15.21% in Q3 2025, an improvement of 549 basis points year-over-year.
• Adjusted EBITDA loss improved by 74% to ($0.19 million) in Q3 2025.
• Cash and cash equivalents increased sharply to $4.63 million as of September 30, 2025, from $0.66 million as of June 30, 2025.
• Secured a $300 million digital financing facility and commenced Ethereum purchases.
• Expanded contract manufacturing, UK sales, and proprietary brands globally, including U.S. operations for Sky Premium Life and entry into Oman.

Sentiment

Score: 8

Explanation: The company reported record operational performance across key metrics like revenue, gross profit, and gross margin. Adjusted profitability significantly improved, and the cash position strengthened substantially. Strategic initiatives like the $300 million digital financing facility and global expansion are positive. The widening GAAP net loss due to non-cash charges is a concern, but the underlying operational trends are very strong.

Positives

• Record Q3 2025 revenue of $17.11 million, representing a 38% increase from Q3 2024.
• Record Q3 2025 gross profit of $2.60 million, a 116% increase from Q3 2024.
• Record gross margin of 15.21% in Q3 2025, an improvement of 549 basis points year-over-year.
• Income from operations loss narrowed to ($1.82 million) in Q3 2025 from ($2.24 million) in Q3 2024.
• Adjusted EBITDA loss improved 74% to ($0.19 million) in Q3 2025 from ($0.70 million) in Q3 2024.
• Adjusted net income loss narrowed to ($0.85 million) in Q3 2025 from ($0.88 million) in Q3 2024.
• Net income loss per share improved to $(0.17) in Q3 2025 from $(0.45) in Q3 2024.
• Adjusted EPS improved to $(0.02) in Q3 2025 and turned positive to $0.02 for the nine-month period, compared with $(0.53) last year.
• Cash and cash equivalents increased significantly to $4.63 million as of September 30, 2025, from $0.66 million as of June 30, 2025.
• Total assets increased to $69.49 million as of September 30, 2025, from $61.84 million as of June 30, 2025.
• Secured a $300 million digital financing facility and commenced Ethereum purchases, strengthening long-term diversification and balance sheet resilience.
• Signed a contract manufacturing agreement with Medical Pharmaquality for the production of 3 million MYCOFAGYL pessaries annually.
• Commenced U.S. operations for the Sky Premium Life brand, with all products manufactured locally in GMP-certified, FDA-registered, and UL-audited facilities.
• Expanded Sky Premium Life across the GCC region, entering Oman through an exclusive distribution agreement and securing an initial purchase order of 42,000 units.
• Strong performance across all core business segments, including Cana Laboratories, Decahedron (UK), and CosmoFarm distribution.
• Strategic investments in talent and new hires, from managerial executives to sales staff and scientific personnel, to support long-term growth.

Negatives

• Total operating expenses increased to $4.42 million in Q3 2025 from $3.45 million in Q3 2024, reflecting strategic investments in talent and operations.
• Net income loss widened to ($5.35 million) in Q3 2025 from ($2.18 million) in Q3 2024, primarily due to non-cash charges related to derivatives, convertible notes, and foreign-currency transactions.
• Total liabilities increased to $46.36 million as of September 30, 2025, from $35.65 million as of June 30, 2025, reflecting the utilization of the digital financing facility.
• Stockholders' equity decreased to $23.13 million as of September 30, 2025, from $26.23 million as of June 30, 2025.

Risks

• The Company's ability to raise sufficient financing to implement its business plan.
• The effectiveness of its digital asset strategies, including accumulation and yield-generating activities.
• The potential impact of the war in Ukraine on the Company's business, operations, and the economy in general.
• The Company's ability to successfully develop and commercialize its proprietary products and technologies.

Future Outlook

The company's trajectory heading into Q4 2025 is even stronger, with a continued focus on growth, disciplined execution, margin expansion, and leveraging its diversified global platform to deliver sustainable, long-term value for shareholders.

Management Comments

• "This was a defining quarter for Cosmos."
• "We not only achieved record revenue and gross profit, but also secured a game-changing $300 million financing facility, enabling us to build a substantial digital assets portfolio and accelerate our long-term strategy to strengthen our core operations and expand our global footprint."
• "Each of our core businesses continues to gain momentum."
• "Our trajectory heading into Q4 2025 is even stronger, and we are excited for what lies ahead."

Industry Context

Cosmos Health operates in the diversified healthcare sector, encompassing pharmaceuticals, nutraceuticals, contract manufacturing, and distribution. The company's strategic move into digital assets (Ethereum) and AI drug repurposing (Cloudscreen) indicates an effort to diversify revenue streams and leverage emerging technologies, aligning with broader trends of digital transformation and innovation in healthcare and finance. Its global expansion, particularly in the U.S. and GCC, reflects a strategy to capture market share in key regions.

Comparison to Industry Standards

• The company's significant revenue growth of 38% year-over-year in Q3 2025 and 13% for the nine-month period suggests strong performance relative to many established healthcare companies, which often experience more moderate growth.
• The substantial improvement in gross margin (549 basis points in Q3) indicates enhanced operational efficiency and a favorable shift in product mix, potentially outperforming industry averages in margin expansion.
• The strategic investment in a $300 million digital financing facility and Ethereum holdings is a unique diversification strategy that sets it apart from traditional healthcare peers, potentially offering higher risk/reward but lacking direct comparable benchmarks within the healthcare sector.
• The expansion of contract manufacturing (e.g., 3 million MYCOFAGYL pessaries annually) and proprietary brands (Sky Premium Life in the U.S. and GCC) demonstrates competitive growth in specific segments, though direct comparable project results are not provided in the filing.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through strong operational growth, strategic diversification into digital assets, and global expansion.
• Employees: Strategic investments in talent and new hires, including managerial executives, sales staff, and scientific personnel, indicate job growth and development opportunities.
• Customers: Expanding pharmacy network (CosmoFarm) and global expansion of proprietary brands (Sky Premium Life, C-Sept/C-Scrub) suggest increased product availability and choice.
• Suppliers: Increased inventory levels and contract manufacturing agreements may lead to increased demand for raw materials and services.
• Creditors: Increased total liabilities due to the financing facility could be a consideration, though the company emphasizes disciplined capital management.

Next Steps

• Continue focusing on growth, disciplined execution, and margin expansion.
• Leverage the diversified global platform to deliver sustainable, long-term value.
• Advance R&D projects powered by the Cloudscreen AI platform.
• Increase investment in patents and intellectual property.
• Further expand global footprint and U.S. operations.

Key Dates

Recommendation

The filing demonstrates robust operational performance with record revenue, gross profit, and gross margin, alongside significant improvements in adjusted EBITDA and cash position. The strategic $300 million digital financing facility and global expansion initiatives position the company for future growth and diversification. While the GAAP net loss widened due to non-cash items, the underlying business momentum and management's positive outlook for Q4 2025 suggest a strong growth trajectory. These factors make the stock an attractive "buy" for investors looking for growth in the diversified healthcare sector with a unique digital asset strategy.

Keywords

healthcare, pharmaceuticals, nutraceuticals, contract manufacturing, distribution, digital assets, Ethereum, Sky Premium Life, Cana Laboratories, Decahedron, CosmoFarm, AI drug repurposing, NASDAQ, COSM